10 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 10 separate news trends connected to Astrazeneca, spanning July 9, 2026 through August 28, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 76 article observations and 71 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
AstraZeneca and Ionis' failed heart disease trial raises questions about the future of RNA drugs
AstraZeneca's failed heart disease drug trial casts doubt on a promising class of treatments
AstraZeneca has abruptly terminated its Phase 3 trial for the lung cancer drug volrustomig, halting development after an internal review.
AstraZeneca's stock surged 6% after a report of merger talks with Bristol Myers Squibb was denied.
Two pharmaceutical giants are in merger talks, potentially reshaping the industry.
AstraZeneca investors react to potential $400 billion merger with Bristol Myers Squibb
AstraZeneca and Bristol Myers Squibb are in talks for a $400bn merger, a deal that would reshape the pharmaceutical industry
Palantir's stock surged over 20% on Tuesday, driving market attention to several key players.
AstraZeneca stock rises as the company reports second-quarter earnings driven by growth in its cancer drug portfolio.
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.